Merck & Co., Inc.
Tažením v grafu vyberte úsek a zobrazí se procentuální změna.Tažením dvěma prsty vyberte úsek a zobrazí se procentuální změna.
Kapitálová struktura
- Tržní kapitalizace
- 365,09 mld. US$
- Enterprise Value
- 412,16 mld. US$
- Hotovost
- 7,14 mld. US$
- Celkový dluh
- 53,91 mld. US$
- Čistý dluh
- 46,77 mld. US$
Valuace (TTM)
- P/E
- 120,31×
- P/E (fwd)
- 15,52×
- P/FCF
- 22,73×
- FCF výnos
- 4,40 %
- EV/EBITDA
- 14,28×
- P/S
- —
- P/B
- 8,71×
- Beta
- 0,23
Marže (TTM)
- Hrubá marže
- 75,90 %
- EBITDA marže
- 43,37 %
- Provozní marže
- -0,24 %
- Čistá marže
- 4,77 %
- FCF marže
- 24,13 %
Ziskovost a růst
- ROE (rentabilita kapitálu)
- 6,96 %
- Růst tržeb (YoY)
- 5,10 %
- Růst zisku (YoY)
- —
Dividenda
- Dividendový výnos
- 2,30 %
- Roční dividenda
- 3,40 US$
- Výplatní poměr
- 268,80 %
- Datum ex-dividendy
- 2026-09-15
52týdenní rozpětí
- Aktuální
- 147,98 US$
- Pozice v pásmu
- 89 %
- Nad ročním minimem
- +90,75 %
- Pod ročním maximem
- -5,70 %
Cena v kontextu
- Historické maximum
- 156,45 US$
- Datum maxima
- 25. 8. 2026
- Zpět na maximum
- +5,72 %
- 200denní průměr
- 121,18 US$
- Odchylka od průměru
- +22,12 %
O společnosti
WebMerck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Vedení společnosti
- Ms. Caroline A. LitchfieldExecutive VP & CFO
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller
- Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Mr. Peter DannenbaumVice President of Investor Relations
- Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health